診所辦公室/實驗室的分散測試和服務趨勢和增長指標

COVID-19 加速了創新，技術先進的便攜式網絡連接加密設備可在幾分鐘內提供結果，正在改變診斷醫學行業。 分散式檢測使臨床醫生能夠為患者做出挽救生命的決定，減少供應鏈滯後，降低現場實驗室檢測成本，縮短住院時間和排隊時間，減少和改善農村地區及時醫療干預的機會。

本報告審視了分佈式測試和服務的趨勢，提供了市場概況/背景、分佈式測試和服務的主要趨勢、增長動力/限制因素、監管環境、商業模式和增長機會。它總結了對

內容

戰略要務

• 增長問題
• 戰略要務 8 (TM)
• 三大戰略要務的影響
• 增長機會推動增長PipelineEngine (TM)

增長機會分析

• 分析範圍
• 分類
• 分佈式檢查和服務的主要趨勢
• 增長動力
• 抑制增長的因素
• 主要監管趨勢：美國
• 主要監管趨勢：歐洲/英國
• 主要監管政策的影響

商業模式/競爭環境

• 隨時隨地互聯健康
• 競爭格局

增長機會領域

• 增長機會：新檢查站的 DaaS（診斷即服務）
• 增長機會：智能家居診所
• 增長機會：農村醫療保健中由藥劑師主導的診斷□□服務
• 成長機會：可預防性失明的視網膜診斷

附錄

Personalized Diagnostics Are at the Cusp of Transformational Growth

Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of in-person clinical examination, reduces the length of hospital stay and wait lines, and helps improve access to rural and semi-urban settings for timely healthcare intervention.

The next-generation point-of-care diagnostics is at an inflection point and is transforming patient care in emergency, acute, chronic, and specialized care with platforms capable of monitoring/measuring a wide range of disease markers with laboratory precision. The diagnostic innovation of assays for rapid detection, miniaturization of portable devices, and automation of workflows serves the broad spectrum of setting and shift toward hyper-scaling of access and comprehensive test designs.

The study showcases several diagnostic technologies, such as a microfluidic-based hand-held portable device (lab-on-a-chip device) designed to provide atraumatic, end-to-end point-of-care automated and integrated diagnostic solution, with its sample-on-chip preparation and nucleic acid analysis assay.

• The recent paper-based devices with Nucleic Acid Testing (NAT) have shown great promise for infectious diseases and detection etiology of infection (bacterial, viral, or fungal) with its cost-effective, bio-compatible, disposable on-site monitoring/testing.

• Lateral flow devices with sensor technology enable rapid analysis of blood samples for many critical care assays. These include blood gases/electrolytes, cardiac markers, cholesterol/lipids, coagulation monitoring, glucose monitoring, hematology, infectious diseases, pregnancy and fertility, tumor/cancer markers, urinalysis, other chemistries (magnesium, lactate, micro-albumin, creatinine), and more.

• Decentralized clinical diagnostics continue to innovate a wide range of systems and assays with rapid test analyzers, instruments, reagents, strips, and cartridges. The electronic services complement it with automation, cloud computing, and deep learning for rapid and accurate results.

Digital technology is accelerating the adoption of decentralization in clinical practice as the workflows integrate with POC at-home systems delivering lab results on smartphones. Integrated, comprehensive diagnostic services are key differentiators for stakeholders, which vary in their offering to enterprises (labs, physician offices, or hospital emergency units) or patients. These services will enhance patient-centered access to care and help physicians close the diagnostic loop of the healthcare continuum.

The regulatory environment analysis of the study provides insight into policies in the US, Europe, and the UK that are currently shaping the implementation of decentralized clinical diagnostics and influencing market adoption.

The study, with an in-depth analysis of the industry environment and its participants, such as clinical laboratories, diagnostic/technology companies, retail, pharmacies, and start-ups, proposes a market model for connected healthcare and the prospective growth opportunities for stakeholders.

Frost & Sullivan predicts the decentralized diagnostic testing market and services to grow exponentially in the next 5 years. This forecast considers structural shifts and economic uncertainties, rising costs, decreasing volumes of COVID-19 tests, government regulations encouraging decentralized care adoption, the discovery of critical assays augmented with AI automation, digital integration, participation of nontraditional players in technology and retail, and more.

Key Issues Addressed:

• Which critical strategic imperatives influence the US, Europe, and the UK's diagnostic testing and service market?

• What are the regulatory trends in the US, Europe, and the UK and their impact on the decentralized testing and service market?

• What are the key segments, trends, market drivers, and restraints?

• What is the new business model and its applications?

• What is the decentralized testing and service market and the competitive landscape?

• What are the key growth opportunities?

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on Decentralized Testing and Service Market
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation
• Key Trends in Decentralized Testing and Services
• Key Trends in Decentralized Testing and Services (continued)
• Growth Drivers
• Growth Restraints
• Key Regulatory Trends-US
• Key Regulatory Trends-Europe-UK
• Key Regulatory Policy Impact

Business Model and Competitive Environment

• Connected Health Everywhere
• Competitive Landscape*

Growth Opportunity Universe

• Growth Opportunity 1: Diagnostics as a Service in Newer Testing Sites
• Growth Opportunity 1: Diagnostics as a Service in Newer Testing Sites (continued)
• Growth Opportunity 2: Home-as-a-Smart Clinic
• Growth Opportunity 2: Home-as-a-Smart Clinic (continued)
• Growth Opportunity 3: Pharmacist-led Diagnostic Services in Rural Health Care
• Growth Opportunity 3: Pharmacist-led Diagnostic Services in Rural Health Care (continued)
• Growth Opportunity 4: Retinal Diagnostics in Preventable Blindness
• Growth Opportunity 4: Retinal Diagnostics in Preventable Blindness (continued)

Appendix

• Abbreviations
• Abbreviations (continued)
• Abbreviations (continued)
• List of Exhibits
• Legal Disclaimer